Literature DB >> 8491241

Sulphation and glucuronidation of ritodrine in human foetal and adult tissues.

G M Pacifici1, M Kubrich, L Giuliani, M de Vries, A Rane.   

Abstract

Ritodrine is a beta 2-adrenoceptor agonist used for the management of preterm labour. It is inactivated by conjugation with sulphate and glucuronic acid. There is more ritodrine sulphate than ritodrine glucuronide in urine from the newborn whereas equal amounts of ritodrine glucuronide and sulphate are excreted in maternal urine [Clin. Pharmacol. Ther 44, 634-641, 1988]. We show that, in the mid-gestational human fetal liver, ritodrine sulphotransferase is well expressed, whereas the glucuronidation of ritodrine is little developed compared to the adult liver. The average sulphotransferase activity was 308 pmol.min-1 per mg protein in fetal (N = 48) and 145 pmol.min-1 per mg protein in adult (N = 32) liver. The rates of ritodrine sulphation in fetal gut, lung and kidney were higher than in the corresponding adult tissues. The development and tissue distribution patterns of ritodrine sulphotransferase are consistent with those of dopamine sulphotransferase. Ritodrine and dopamine are sulphated by thermolabile enzymes. The activity of glucuronyl transferase was measurable in only 5 of the 48 foetal livers assayed, and in those in which could be assayed, the average activity was 44.6 pmol.min-1 per mg protein, one-tenth of that in adult livers (524 pmol.min-1 per mg protein).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491241     DOI: 10.1007/BF00271368

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

Review 1.  Molecular enzymology of human liver cytosolic sulfotransferases.

Authors:  C N Falany
Journal:  Trends Pharmacol Sci       Date:  1991-07       Impact factor: 14.819

2.  Dopamine sulphotransferase is better developed than p-nitrophenol sulphotransferase in the human fetus.

Authors:  M Cappiello; L Giuliani; A Rane; G M Pacifici
Journal:  Dev Pharmacol Ther       Date:  1991

3.  Differential distribution of phenol and catechol sulphotransferases in human liver and intestinal mucosa.

Authors:  M Cappiello; L Giuliani; G M Pacifici
Journal:  Pharmacology       Date:  1990       Impact factor: 2.547

4.  Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus.

Authors:  G M Pacifici; M Franchi; L Giuliani; A Rane
Journal:  Dev Pharmacol Ther       Date:  1989

5.  Rat brain phenolsulfotransferase: partial purification and some properties.

Authors:  A Foldes; J L Meek
Journal:  Biochim Biophys Acta       Date:  1973-12-19

6.  Development of multiple activities of UDP-glucuronyltransferase in human liver.

Authors:  J E Leakey; R Hume; B Burchell
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

7.  Development of human liver UDP-glucuronosyltransferases.

Authors:  B Burchell; M Coughtrie; M Jackson; D Harding; S Fournel-Gigleux; J Leakey; R Hume
Journal:  Dev Pharmacol Ther       Date:  1989

8.  Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isozymes of the thermostable form.

Authors:  N R Campbell; J A Van Loon; R M Weinshilboum
Journal:  Biochem Pharmacol       Date:  1987-05-01       Impact factor: 5.858

9.  Sulfotransferase in humans: development and tissue distribution.

Authors:  G M Pacifici; M Franchi; C Colizzi; L Giuliani; A Rane
Journal:  Pharmacology       Date:  1988       Impact factor: 2.547

10.  Morphine glucuronidation in human fetal and adult liver.

Authors:  G M Pacifici; J Säwe; L Kager; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more
  16 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Sulfation of ritodrine by the human cytosolic sulfotransferases (SULTs): Effects of SULT1A3 genetic polymorphism.

Authors:  Ying Hui; Ming-Cheh Liu
Journal:  Eur J Pharmacol       Date:  2015-05-02       Impact factor: 4.432

3.  Genetic variation, expression and ontogeny of sulfotransferase SULT2A1 in humans.

Authors:  L Ekström; A Rane
Journal:  Pharmacogenomics J       Date:  2015-03-24       Impact factor: 3.550

4.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Updated perspectives on the cytosolic sulfotransferases (SULTs) and SULT-mediated sulfation.

Authors:  Masahito Suiko; Katsuhisa Kurogi; Takuyu Hashiguchi; Yoichi Sakakibara; Ming-Cheh Liu
Journal:  Biosci Biotechnol Biochem       Date:  2016-09-21       Impact factor: 2.043

6.  Ritodrine sulphation in the human liver and duodenal mucosa: interindividual variability.

Authors:  G M Pacifici; M C Quilici; B Giulianetti; R Spisni; M Nervi; L Giuliani; R Gomeni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

Review 7.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  (+) and (-) terbutaline are sulphated at a higher rate in human intestine than in liver.

Authors:  G M Pacifici; M Eligi; L Giuliani
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Interindividual variability of phenol- and catechol-sulphotransferases in platelets from adults and newborns.

Authors:  G M Pacifici; G Marchi
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

10.  Human liver budesonide sulphotransferase is inhibited by testosterone and correlates with by testosterone sulphotransferase.

Authors:  G M Pacifici; M A Ferroni; A Temellini; A Gucci; M C Morelli; L Giuliani
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.